CERo Therapeutics Holdings, Inc. CERO
0.01 USD 0.00 (+25.00%)
Nov 3, 2026, 3:13 PM EST
0.0038 Day range 0.005
0.003 52-week range 0.209
- YTD
- -92.54%
- 1 year
- -92.96%
- Market cap
- 358.15K
- EPS (ttm)
- 40.34
- Shares out
- 150.31M
- P/E ratio
- 0.00
- YTD return
- -92.54%
- 1-year return
- -92.96%
- Volume
- 133.61K
- Avg volume
- 626.06K
- Open
- 0.0038
- Previous close
- 0.004
- Day's range
- 0.0038 – 0.005
- 52-week range
- 0.003 – 0.209
- Beta
- -0.46
2Y -149.9960 (-100.00%)
Key statistics
- Enterprise value
- 20.56M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 14.46M
- Total cash
- 3.65M
- Total debt
- 2.15M
- Return on equity
- 0.00%
- Short % of float
- 2.08%
- 50-day average
- 0.12674
- 200-day average
- 0.62712
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
CERO Revenue — quarterly 0
CERO Net income — quarterly -5.42M
CERO EPS — quarterly -61.71
About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cero.bio
News
CERo Therapeutics Doses 7th Patient in Phase 1 CER-1236 Trial 
CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies 
SRX Global Says UC Davis Activated As Clinical Trial Site For CERTAIN-T, Ongoing Phase 1 Study Evaluating CER-1236 In Patients With Hematologic Malignancies Being Conducted By CERo Therapeutics 
CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers 
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment - CERo Therapeutics Hldgs Q1 EPS $(0.20) Beats $(1.00) Estimate
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial 
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial 
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial 
CERo Therapeutics Provides Shareholder Update
Your note
Sign in to keep a note on CERO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ATWOOD BRIAN G | Director | Conversion of Exercise of derivative security | Sep 24, 2024 | 0 |
| EHRLICH CHRISTOPHER B | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 24, 2024 | 5,795,410 |
| LAPORTE KATHLEEN D | Director | Conversion of Exercise of derivative security | Sep 24, 2024 | 0 |
| SLOAN STUART M | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 24, 2024 | 0 |
| YK BIOVENTURES OPPORTUNITIES GP I, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Dec 12, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Arch Venture Management, Llc | 0.96% | 1,444,296 | 72.94K | Sep 29, 2024 |
| Avantax Planning Partners, Inc. | 0.91% | 1,361,130 | 68.74K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.10% | 157,445 | 7.95K | Sep 29, 2024 |
| Selkirk Management Llc | 0.08% | 121,040 | 6.11K | Sep 29, 2024 |
| HRT Financial LP | 0.05% | 79,562 | 4.02K | Sep 29, 2024 |
| Fifth Lane Capital, LP | 0.05% | 76,593 | 3.87K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.10% | 144,145 | 7.28K | Oct 30, 2024 |